<DOC>
	<DOCNO>NCT01370239</DOCNO>
	<brief_summary>The humanized monoclonal antibody Lewis Y antigen ( Hu3S193 ) demonstrate safe previous study also indicate potential intervention breast cancer . The study new agent advance breast cancer may contribute development new strategy patient progress hormonal treatment .</brief_summary>
	<brief_title>HumanaH - Hu3s193 Treatment Advanced Breast Cancer After Hormonal Therapy</brief_title>
	<detailed_description>This national study , open label , single arm , phase II study conduct seven center Brazil . The study coordinate INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO collaboration RECEPTA Biopharma . The study fund CONSELHO NACIONAL DE DESENVOLVIMENTO CIENTÍFICO E TECNOLÓGICO ( CNPq ) . Before procedure relating study , patient must read sign inform consent ( IC ) . The inclusion patient begin immediately regulatory approval expect end reach number patient . The follow-up term last least 24 month patient include , unless limit death , loss follow withdrawal inform consent . A total 60 patient recruit study . The eligible patient must 18 old , confirm diagnosis breast cancer locally advance metastatic progression one two line previous hormone treatment , confirmation Lewis antigen expression -as assess central laboratory , measurable evaluable disease adequate organ function . Patients receive weekly intravenous dos antibody Hu3S193 disease progression , unacceptable toxicity , withdrawal consent investigator 's decision , whichever occur first . The study 's primary endpoint clinical benefit rate .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Diagnosis breast cancer locally advance metastatic ( stage IIIB , IIIC IV accord TNM classification ) , confirm histologically intention curative treatment radiotherapy surgery ; Clinical radiological progression one two line previous hormone treatment , include adjuvant treatment ; Positive ER / PR expression document IHC ; Confirmed expression Lewis Y antigen IHC ; Presenting performance status 0 1 accord Eastern Cooperative Oncology Group ( ECOG ) ; Have measurable evaluable disease Response Evaluation Criteria Solid Tumors ( RECIST ) ; Adequate organ function , assessed laboratory test obtain least 2 week first day treatment within follow parameter : absolute neutrophil count ≥ 1.5 x 109 / L ; platelet count ≥ 100 x 109 / L ; serum bilirubin ≤ 2.0 mg / dL ; AST/ALT ≤ 2.5 x upper limit normal ; serum creatinine ≤ 2.0 mg / dL ; Expected survival &gt; 12 week ; In patient childbearing potential : Negative pregnancy confirm test do 21 day date study treatment initiation ; Willingness ability comply protocol duration study . Patients subject previously two line hormonal therapy , include adjuvant treatment ; Presenting amplification overexpression HER2 ; Systemic corticosteroid immunosuppressive agent use concomitantly study use systemic corticosteroid immunosuppressant last 14 day first dose investigational drug ; Visceral metastatic disease lifethreatening ( defined extensive liver involvement ) , symptomatic pulmonary lymphangitic carcinomatosis degree cerebral leptomeningeal involvement ; Previous current history clinically significant cardiac disease ( class III IV accord New York Heart Association ) ; Clinically significant arrhythmia ; History myocardial infarction within last 6 month ; Previous current history severe disease ( eg , severe ascites require repeat drainage , active infection require antibiotic , bleeding , inflammatory bowel disease chronic disease may interfere obtain accurate result study ) ; Previous chemotherapy metastatic disease ( adjuvant chemotherapy acceptable , four week completion inclusion study ; Radiotherapy within 4 week inclusion study recovery toxic effect radiotherapy do 6 week inclusion study , except palliative radiotherapy bone metastases involve &lt; 25 % bone marrow ; Treatment biological agent , immunotherapy surgery within 4 week inclusion study recovery toxic effect treatment make six week prior study entry ( prior treatment bisphosphonates allow , continue inclusion study ) ; Any investigational agent treatment within 12 month prior study entry , unless investigator considers participation study may benefit patient ; Previous current history another type tumor , exclude skin cancer , melanoma , situ cervix carcinoma situ ductal carcinoma lobular breast properly treat ; Uncontrolled hypercalcemia ( defined total calcium &gt; 11.5 mg / dL )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>monoclonal antibody</keyword>
	<keyword>Lewis</keyword>
	<keyword>breast cancer</keyword>
</DOC>